Is surgery the next answer to treat obesity-related hypertension?

Journal of Clinical Hypertension

Volumn 11, Issue 5, 2009, Pages 284-288

  Frezza, Eldo E ^a   Wei, Cai ^b   Wachtel, Mitchell S ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADRENERGIC SYSTEM; ALDOSTERONE BLOOD LEVEL; BARIATRIC SURGERY; BEHAVIOR THERAPY; BLOOD PRESSURE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; COMORBIDITY; DIABETES MELLITUS; EXERCISE; FOOD INTAKE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY TUBULE ABSORPTION; LIFESTYLE MODIFICATION; NATRIURESIS; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SLEEP APNEA SYNDROME; SURGICAL TECHNIQUE; UNITED STATES; WEIGHT REDUCTION;

BARIATRIC SURGERY; HUMANS; HYPERTENSION; OBESITY; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 66649083452     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00123.x     Document Type: Review

References (52)

1. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.
2. Bult MJ, van Dalen T, Muller AF Surgical treatment of obesity. Eur J Endocrinol. 2008;158:135-145.
3. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
4. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39-47.
5. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
6. Wolf AM, Colditz GA. The cost of obesity: The US perspective. Pharmacoeconomics. 1994;5(suppl):34-37.
7. John E. Hall the kidney, hypertension, and obesity. Hypertension. 2003;41:625.
8. Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 2007;10:1151-1155.
9. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone. Hypertension. 2004;43:518.
10. Zalesin KC, McCullough PA. Bariatric surgery for morbid obesity: Risks and benefits in chronic kidney disease patients. Adv Chronic Kidney Dis. 2006;13:403-417.
11. Mark AL. Weight reduction for treatment of obesity-associated hypertension: Nuances and challenges. Curr Hypertens Rep. 2007;9:368-372.
12. Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial-the Hypertension Control Program. JAMA. 1987;257:1484-1491.
13. Palinkas LA, Wingard DL, Barrett-Connor E. Depressive symptoms in overweight and obese older adults: A test of the "jolly fat" hypothesis. J Psychosom Res. 1996;40:59-66.
14. Tsai AG, Wadden TA. Systematic review: An evaluation of major commercial weight loss programs in the United States. Ann Intern Med. 2005;142:56-66.
15. Li Z, Maglione M, Tu W, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.
16. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al; For the RIO-North America study group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. J Am Med Assoc. 2006;295:761-775.
17. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomized controlled study. Lancet. 2006;368:1660-1672.
18. Van Gaal LF, Rissanen AM, Scheen AJ, et al; For the RIO-Europe study group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397.
19. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591-602.
20. Di Vetta V, Kraytem A, Giusti V. Gastric bypass: Management of complications and food tolerance. Rev Med Suisse. 2008;151:836-838.
21. Kawamura I, Ochiai T. Current status of obesity surgery as metabolic surgery. Nippon Geka Gakkai Zasshi. 2006;107:305-311.
22. O'Brien PE, Brown WA, Dixon JB. Obesity, weight loss and bariatric surgery. Med J Aust. 2005;183:310-314.
23. Andersen T, Stokholm KH, Backer OG, et al. Long-term (5-year) results after either horizontal gastroplasty or very- low-calorie diet for morbid obesity. Int J Obes. 1988;12:277-284.
24. Hall JC, Watts JM, O'Brien PE, et al. Gastric surgery for morbid obesity. The adelaide study. Ann Surg. 1990;211:419-427.
25. Naslund I, Wickbom G, Christoffersson E, et al. A prospective randomized comparison of gastric bypass and gastroplasty. Complications and early results. Acta Chir Scand. 1986;152:681-689.
26. Lechner GW, Elliott DW. Comparison of weight loss after gastric exclusion and partitioning. Arch Surg. 1983;118:685-692.
27. Ashley S, Bird DL, Sugden G, et al. Vertical banded gastroplasty for the treatment of morbid obesity. Br J Surg. 1993;80:1421-1423.
28. Dixon JB, O'Brien PE. Changes in comorbidities and improvements in quality of life after LAP-BAND placement. Am J Surg. 2002;184:51S-54S.
29. Flum DR, Salem L, Elrod JA, et al. Early mortality among medicare beneficiaries undergoing bariatric surgical procedures. J Am Med Assoc. 2005;294:1903-1908.
30. Frezza EE, Barton A, Herbert H, et al. Laparoscopic sleeve gastrectomy with endoscopic guidance in morbid obesity. Surg Obes Relat Dis. 2008;4:575-579.
31. Frezza EE, Chiriva-Internati M, Wachtel MS. Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin. Surg Today. 2008;38:481-483.
32. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology. 2001;120:669-681.
33. Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: Surgical treatment of obesity. Ann Intern Med. 2005;142:547-559.
34. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: A systematic review and meta-analysis. J Am Med Assoc. 2004;292:1724-1737.
35. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
36. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity and health care use in morbidly obese patients. Ann Surg. 2004;240:416-423.
37. Frezza EE, Wachtel M, Ewing BT. The economic impact of morbid obesity on the state economy: An initial evaluation. Surg Obes Relat Dis. 2006;2:504-508.
38. Kushner RF, Noble CA. Long-term outcome of bariatric surgery: An interim analysis. Mayo Clin Proc. 2006;81(suppl 10):S46-S51.
39. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. JAMA. 2004;292:1724-1737.
40. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA. 2008;299:316-323.
41. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-242.
42. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741-749.
43. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10years after bariatric surgery. New Engl J Med. 2004;351:2683-2693.
44. Maher JW, Hawver LM, Pucci A, et al. Four hundred fifty consecutive laparoscopic Roux-en-Y gastric bypasses with no mortality and declining leak rates and lengths of stay in a bariatric training program. J Am Coll Surg. 2008;206:940-944.
45. Gomez V, Riall TS, Gomez GA. Outcomes in bariatric surgery in the older patient population in Texas. J Surg Res. 2008;147:270-275.
46. Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2008;3(suppl 3):S47-S55.
47. Khalaileh A, Matot I, Schweiger C, et al. Laparoscopic Roux-en-Y gastric bypass for the treatment of morbid obesity: Experience with 50 patients. Isr Med Assoc J. 2008; 10: 350-353.
48. Debrunner M, Schuiki E, Minder E, et al. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol. 2008;97:298-305.
49. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
50. Wang B, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch. 2006;452:418-427.
51. Hector J, Schwarzloh B, Goehring J, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res. 2007;39:250-255.
52. Mateo T, Naim Abu Nabh Y, Losada M, et al. A critical role for TNF-alpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles. Blood. 2007;110:1895-1902.